Naloxegolinteractions
naloxegol 25 MG Oral Tablet [Movantik]
This is the interactions section of this product’s FDA label — what the manufacturer documented for this drug. It is not a check of your medication list, and a drug missing from it has not been cleared: licensed clinical databases list far more interactions than any single label does. Before combining medicines, ask a pharmacist, who can check everything you take at once and will do it for free.
Named on this label
- clarithromycin
- carbamazepine
- erythromycin
- itraconazole
- ketoconazole
- cimetidine
- diltiazem
- quinidine
- verapamil
- rifampin
Every name above is printed in the text below. This is not the full set of drugs that interact with this one — it is the set this manufacturer wrote down.
Drug interactions
Moderate CYP3A4 inhibitors (e.g., diltiazem, erythromycin, verapamil): Increased naloxegol concentrations; avoid concomitant use; if unavoidable, reduce dosage to 12.5 mg once daily and monitor for adverse reactions. Strong CYP3A4 inducers (e.g., rifampin): Decreased concentrations of naloxegol; concomitant use is not recommended.
Other opioid antagonists: Potential for additive effect and increased risk of opioid withdrawal; avoid concomitant use.
7.1 Effects of
Other Drugs on MOVANTIK Table 2 displays the effects of other drugs on MOVANTIK. Table 2. Effects of Other Drugs on MOVANTIK Concomitant Agent Mechanism of Action Clinical Recommendation CYP3A4 Inhibitors
Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin)
Increase plasma naloxegol concentrations and may increase the risk of adverse reactions.
Use with strong CYP3A4 inhibitors is contraindicated.
Moderate CYP3A4 inhibitors (e.g., diltiazem, erythromycin, verapamil)
Avoid use with moderate CYP3A4 inhibitors; if unavoidable, decrease the dosage of MOVANTIK to 12.5 mg once daily and monitor for adverse reactions.
Weak CYP3A4 inhibitors (e.g., quinidine, cimetidine)
Clinically significant increases in naloxegol concentrations are not expected.
No dosage adjustments are necessary.
Grapefruit or grapefruit juice The effect of grapefruit juice varies widely among brands and is concentration-, dose-, and preparation-dependent. Studies have shown that it can be classified as a “strong CYP3A inhibitor” when a certain preparation was used (e.g., high dose, double strength) or as a “moderate CYP3A inhibitor” when another preparation was used (e.g., low dose, single strength).
Can increase plasma naloxegol concentrations.
Avoid consumption of grapefruit or grapefruit juice during treatment with MOVANTIK. CYP3A4 Inducers
Strong CYP3A4 inducers (e.g., rifampin, carbamazepine, St. John’s Wort)
Significantly decrease plasma naloxegol concentrations and may decrease the efficacy of MOVANTIK.
Use with strong CYP3A4 inducers is not recommended. Other Drug Interactions
Other opioid antagonists
Potential for additive effect of opioid receptor antagonism and increased risk of opioid withdrawal.
Avoid use of MOVANTIK with another opioid antagonist.
Text above is quoted in full from the FDA-approved drug label published by openFDA, effective December 22, 2025. Matched to this product by RxNorm code. Cross-references to other sections of the full prescribing information have been removed, since they point to a document not shown here. Nothing else is changed: no sentence is shortened, reworded or summarised.
This page reproduces regulatory text for reference. It is not medical advice, and KenyRx is not a pharmacy or a prescriber. Talk to a doctor or pharmacist about whether a medicine is right for you.
See what it costs — price without insurance